We are using cookies to give you the best experience on our site. Cookies are files stored in your browser and are used by most websites to help personalise your web experience. By continuing to use our website without changing the settings, you are agreeing to our use of cookies.

Share
  • Facebook
  • Twitter
  • Linked In
  • Google+
back top
Vericel (VCEL): Revenue Growth Fueled by Three Cellular Therapies

1300 members from 70 countries Join ICRS

Vericel (VCEL): Revenue Growth Fueled by Three Cellular Therapies

Vericel (Nasdaq: VCEL), a specialty biologics company with three approved cellular therapy products on the market might still be underappreciated by investors after its recent run?

Vericel’s second quarter numbers, reported earlier this month, showed strong growth in revenues and gross margin year-over-year, driven by sales of its newly introduced MACI implant for the treatment of symptomatic cartilage defects in the knee.

Read More…

Vericel (Nasdaq: VCEL), a…
ICRShttps://cartilage.org/content/uploads/icrs.jpg
Vericel (VCEL): Revenue Growth Fueled by Three Cellular Therapies